相似文献
1
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.
2
Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.
Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1453-1459. doi: 10.1007/s10096-024-04840-9. Epub 2024 Apr 27.
3
Treatment-emergent cefiderocol resistance in carbapenem-resistant is associated with insertion sequence IS in the siderophore receptor .
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0029024. doi: 10.1128/aac.00290-24. Epub 2024 May 29.
4
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.
5
Accumulation of Antibiotic Resistance Genes in Carbapenem-Resistant Isolates Belonging to Lineage 2, Global Clone 1, from Outbreaks in 2012-2013 at a Tehran Burns Hospital.
mSphere. 2020 Apr 8;5(2):e00164-20. doi: 10.1128/mSphere.00164-20.
6
Adaptations of carbapenem resistant (CRAB) in the hospital environment causing sustained outbreak.
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001345. Epub 2021 Mar 19.
7
First detection of a cefiderocol-resistant and extensively drug-resistant Acinetobacter baumannii clinical isolate in Bulgaria.
Acta Microbiol Immunol Hung. 2024 Jan 23;71(1):25-36. doi: 10.1556/030.2024.02201. Print 2024 Mar 26.
8
Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.
BMC Infect Dis. 2016 May 4;16:194. doi: 10.1186/s12879-016-1526-y.
9
Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing Carried on a Plasmid.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00797-17. Print 2017 Nov.
10
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.
Microbiol Spectr. 2024 Oct 3;12(10):e0093024. doi: 10.1128/spectrum.00930-24. Epub 2024 Aug 20.
引用本文的文献
1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
3
Comparative activity of sulbactam with avibactam or durlobactam against carbapenem-resistant .
JAC Antimicrob Resist. 2025 Jun 23;7(3):dlaf098. doi: 10.1093/jacamr/dlaf098. eCollection 2025 Jun.
4
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
5
Heterogeneity and Genomic Plasticity of Acinetobacter baumannii and Acinetobacter nosocomialis Isolates Recovered from Clinical Samples in India.
Curr Microbiol. 2024 Oct 19;81(12):415. doi: 10.1007/s00284-024-03942-z.
6
Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii.
NPJ Biofilms Microbiomes. 2024 Sep 30;10(1):92. doi: 10.1038/s41522-024-00560-2.
7
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant infections.
JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146. doi: 10.1093/jacamr/dlae146. eCollection 2024 Oct.
8
Challenges Facing Two Outbreaks of Carbapenem-Resistant : From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants.
Antibiotics (Basel). 2024 Aug 21;13(8):784. doi: 10.3390/antibiotics13080784.
9
transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- drug development and AMR preparedness.
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0022224. doi: 10.1128/aac.00222-24. Epub 2024 Aug 27.
10
Unveiling the Secrets of : Resistance, Current Treatments, and Future Innovations.
Int J Mol Sci. 2024 Jun 21;25(13):6814. doi: 10.3390/ijms25136814.
本文引用的文献
1
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance.
mBio. 2022 Apr 26;13(2):e0275921. doi: 10.1128/mbio.02759-21. Epub 2022 Mar 21.
2
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
3
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists.
Infect Dis Ther. 2021 Dec;10(4):2177-2202. doi: 10.1007/s40121-021-00541-4. Epub 2021 Oct 14.
4
Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 4;69(48):1827-1831. doi: 10.15585/mmwr.mm6948e1.
5
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
6
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.
7
Microbiome in the setting of burn patients: implications for infections and clinical outcomes.
Burns Trauma. 2020 Aug 14;8:tkaa033. doi: 10.1093/burnst/tkaa033. eCollection 2020.
8
CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database.
Nucleic Acids Res. 2020 Jan 8;48(D1):D517-D525. doi: 10.1093/nar/gkz935.
9
Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications.
Wellcome Open Res. 2018 Sep 24;3:124. doi: 10.12688/wellcomeopenres.14826.1. eCollection 2018.
10
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
Zotero 插件